In last trading session, Adaptive Biotechnologies Corp (NASDAQ:ADPT) saw 2.36 million shares changing hands with its beta currently measuring 1.72. Company’s recent per share price level of $7.89 trading at $0.51 or 6.91% at ring of the bell on the day assigns it a market valuation of $1.17B. That closing price of ADPT’s stock is at a discount of -14.2% from its 52-week high price of $9.01 and is indicating a premium of 68.57% from its 52-week low price of $2.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.14 million shares which gives us an average trading volume of 1.95 million if we extend that period to 3-months.
For Adaptive Biotechnologies Corp (ADPT), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 11 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.31 in the current quarter.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Upright in the green during last session for gaining 6.91%, in the last five days ADPT remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $7.89 price level, adding 1.74% to its value on the day. Adaptive Biotechnologies Corp’s shares saw a change of 31.61% in year-to-date performance and have moved 5.34% in past 5-day. Adaptive Biotechnologies Corp (NASDAQ:ADPT) showed a performance of -6.29% in past 30-days. Number of shares sold short was 10.12 million shares which calculate 4.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 43.64% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 36.63% in reaching the projected high whereas dropping to the targeted low would mean a gain of 36.63% for stock’s current value.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
This year revenue growth is estimated to rise 18.85% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 42.13M for the same. And 6 analysts are in estimates of company making revenue of 47.3M in the next quarter. Company posted 41.87M and 43.19M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.51% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 14.59% while estimates for its earnings growth in next 5 years are of 28.67%.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Insiders are in possession of 2.39% of company’s total shares while institution are holding 94.24 percent of that, with stock having share float percentage of 96.55%. Investors also watch the number of corporate investors in a company very closely, which is 94.24% institutions for Adaptive Biotechnologies Corp that are currently holding shares of the company. VIKING GLOBAL INVESTORS LP is the top institutional holder at ADPT for having 29.99 million shares of worth $108.58 million. And as of 2024-06-30, it was holding 20.3466 of the company’s outstanding shares.
The second largest institutional holder is RUBRIC CAPITAL MANAGEMENT LP, which was holding about 14.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4971 of outstanding shares, having a total worth of $50.68 million.
On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 7.62 shares of worth $60.12 million or 5.13% of the total outstanding shares. The later fund manager was in possession of 4.2 shares on Dec 31, 2024 , making its stake of worth around $33.12 million in the company or a holder of 2.83% of company’s stock.
